Diana Ernst, RPh

Editorial Director https://www.cancertherapyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Overselling scientific data contributes to misunderstanding, failure, and disappointment in real-wor

General Oncology

FDA: Nitrosamine Impurity Identified in Commonly Used Acid Suppressant

Diana Ernst, RPh

September 16, 2019

NDMA was one of several nitrosamine impurities implicated in the massive recall of angiotensin II receptor blockers (ARBs) since last year.

General Oncology

Review: Medications Linked to Hyperlactatemia, Lactic Acidosis

Diana Ernst, RPh

August 1, 2019

In the study, albuterol and epinephrine were tied to the most cases after excluding metformin and NRTIs.

General Oncology

Biosimilars Mvasi, Kanjinti Now Available in the US

Diana Ernst, RPh

July 22, 2019

Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.

Multiple Myeloma

Darzalex Gets Approval for Additional Multiple Myeloma Indication

Diana Ernst, RPh

June 28, 2019

The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Lung Cancer

Keytruda Approved to Treat Metastatic Small Cell Lung Cancer

Diana Ernst, RPh

June 18, 2019

The approval was based on data from 83 patients with SCLC who were enrolled in either the KEYNOTE-028 or KEYNOTE-158 trials.

Breast Cancer

Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer

Diana Ernst, RPh

June 18, 2019

Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.

Head and Neck Cancer

Keytruda Approved for First Line Treatment of Unresectable, Recurrent HNSCC

Diana Ernst, RPh

June 12, 2019

The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.

Breast Cancer

First-in-Class Treatment Approved for Advanced Breast Cancer

Diana Ernst, RPh

May 28, 2019

The FDA has approved Piqray (alpelisib; Novartis) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Lung Cancer

Treatment for Malignant Pleural Mesothelioma Gets FDA Approval

Diana Ernst, RPh

May 28, 2019

The FDA has approved the NovoTTF-100L System (Novocure) in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma.

Chronic Lymphocytic Leukemia

Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL

Diana Ernst, RPh

May 16, 2019

The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Next post in Chronic Lymphocytic Leukemia